Product Description
Mechanisms of Action: ADORA3 Stimulant
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: OncoVista
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Leukemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ChiCTR2400088428 | N/A |
Not yet recruiting |
Asthenia |
2027-02-28 |
|
| ChiCTR2300075042 | N/A |
Recruiting |
Non-Small-Cell Lung Cancer|Small Cell Lung Cancer |
2025-06-01 |
|
| ChiCTR-INR-17014074 | N/A |
Not yet recruiting |
Depressive Disorder, Major |
2019-12-31 |
|
| OV06-001 | P2 |
Unknown status |
Leukemia |
2010-12-01 |